Loading…

Merck announced plans to construct a new manufacturing facility at its Maurice R. Hilleman Center in Durham, North Carolina, to triple production capacity for TICE BCG bladder cancer medicine. Construction is expected to take 5-6 years.
“Once this new facility is fully operational, we will triple the company’s current manufacturing capacity, which is expected to support the anticipated demand for TICE BCG for the foreseeable future.”merck.com
Summarized from public sources; check the original articles before acting on it.